Skip to main content

Compare Stocks

Date Range: 

 Bio-Rad LaboratoriesAvantorWaters10x Genomics
SymbolNYSE:BIONYSE:AVTRNYSE:WATNASDAQ:TXG
Price Information
Current Price$589.74$30.90$308.94$143.83
52 Week RangeBuyBuyHoldBuy
MarketRank™
Overall Score1.52.01.32.0
Analysis Score2.53.50.94.4
Community Score2.43.02.03.3
Dividend Score0.00.00.00.0
Ownership Score0.81.71.71.7
Earnings & Valuation Score1.91.91.90.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuy
Consensus Price Target$700.00$34.87$251.25$181.44
% Upside from Price Target18.70% upside12.84% upside-18.67% downside26.15% upside
Trade Information
Market Cap$17.88 billion$17.99 billion$19.27 billion$15.64 billion
Beta0.831.840.971.39
Average Volume193,4414,429,942372,775800,407
Sales & Book Value
Annual Revenue$2.31 billion$6.04 billion$2.41 billion$245.89 million
Price / Sales7.592.987.9263.61
Cashflow$6.99 per share$2.00 per share$16.40 per shareN/A
Price / Cash84.4215.4518.84N/A
Book Value$192.32 per share$2.55 per share($3.36) per share$4.36 per share
Price / Book3.0712.12-91.9532.99
Profitability
Net Income$1.76 billion$37.80 million$592.20 million$-31,250,000.00
EPS$7.06$0.58$8.99($0.80)
Trailing P/E Ratio5.05257.5038.47N/A
Forward P/E Ratio57.8228.3534.83N/A
P/E GrowthN/A1.078.79N/A
Net Margins147.91%2.21%22.61%-51.27%
Return on Equity (ROE)3.77%44.58%-349.31%-19.98%
Return on Assets (ROA)2.74%6.85%21.11%-14.38%
Dividend
Annual PayoutN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A3.27%N/AN/A
Current Ratio2.36%2.02%1.82%6.19%
Quick Ratio1.71%1.38%1.33%6.01%
Ownership Information
Institutional Ownership Percentage63.03%84.79%91.80%68.84%
Insider Ownership Percentage27.50%1.90%1.50%13.28%
Miscellaneous
Employees8,00012,4007,400852
Shares Outstanding29.76 million582.14 million61.70 million108.75 million
Next Earnings Date7/29/2021 (Estimated)8/4/2021 (Estimated)7/27/2021 (Estimated)8/10/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
10x Genomics, Inc. (NASDAQ:TXG) Insider Bradford Crutchfield Sells 17,000 Shares10x Genomics, Inc. (NASDAQ:TXG) Insider Bradford Crutchfield Sells 17,000 Shares
americanbankingnews.com - May 13 at 9:44 PM
10x Genomics (NASDAQ:TXG) Shares Gap Up to $134.2210x Genomics (NASDAQ:TXG) Shares Gap Up to $134.22
americanbankingnews.com - May 13 at 10:58 AM
10x Genomics (NASDAQ:TXG) Updates FY 2021 Earnings Guidance10x Genomics (NASDAQ:TXG) Updates FY 2021 Earnings Guidance
americanbankingnews.com - May 12 at 11:00 AM
US$208 - Thats What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These ResultsUS$208 - That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results
nasdaq.com - May 8 at 2:55 PM
10x Genomics Inc. [TXG] is 2.01% higher this YTD. Is it still time to buy?10x Genomics Inc. [TXG] is 2.01% higher this YTD. Is it still time to buy?
dbtnews.com - May 7 at 5:56 PM
What Did We Learn From 10x Genomics, Inc. (NASDAQ:TXG) Insider Trading?What Did We Learn From 10x Genomics, Inc. (NASDAQ:TXG) Insider Trading?
stocksregister.com - May 6 at 4:54 PM
Oversold Conditions For 10x Genomics (TXG)Oversold Conditions For 10x Genomics (TXG)
nasdaq.com - May 6 at 4:54 PM
10x Genomics (NASDAQ:TXG) Releases Quarterly  Earnings Results, Beats Estimates By $0.14 EPS10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS
americanbankingnews.com - May 6 at 3:24 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down  Following Insider Selling10x Genomics (NASDAQ:TXG) Shares Gap Down Following Insider Selling
americanbankingnews.com - May 6 at 11:34 AM
Why Investors Didnt Like 10x Genomics Q1 ResultsWhy Investors Didn't Like 10x Genomics' Q1 Results
msn.com - May 6 at 7:19 AM
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 5 at 11:04 PM
10x Genomics: Q1 Earnings Snapshot10x Genomics: Q1 Earnings Snapshot
sfgate.com - May 5 at 9:18 PM
John R. Stuelpnagel Sells 7,500 Shares of 10x Genomics, Inc. (NASDAQ:TXG) StockJohn R. Stuelpnagel Sells 7,500 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock
americanbankingnews.com - May 5 at 8:32 PM
10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $2,761,200.00 in Stock10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $2,761,200.00 in Stock
americanbankingnews.com - May 5 at 7:58 PM
10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $1,919,300.00 in Stock10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $1,919,300.00 in Stock
americanbankingnews.com - May 5 at 7:58 PM
10x Genomics, Inc. (NASDAQ:TXG) Insider Sells $7,993,205.44 in Stock10x Genomics, Inc. (NASDAQ:TXG) Insider Sells $7,993,205.44 in Stock
americanbankingnews.com - May 5 at 7:58 PM
A Trigger to Get Long: Three Inside Up, RSI, Moving Average Trigger in 10x Genomics IncA Trigger to Get Long: Three Inside Up, RSI, Moving Average Trigger in 10x Genomics Inc
cmlviz.com - May 5 at 4:17 PM
10x Genomics Reports First Quarter 2021 Financial Results10x Genomics Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 5 at 4:17 PM
10x Genomicss Earnings: A Preview10x Genomics's Earnings: A Preview
benzinga.com - May 4 at 2:21 PM
10x Genomics (NASDAQ:TXG) Trading Down 4.1%10x Genomics (NASDAQ:TXG) Trading Down 4.1%
americanbankingnews.com - May 3 at 12:44 PM
10x Genomics to Present at the BofA Securities 2021 Virtual Healthcare Conference10x Genomics to Present at the BofA Securities 2021 Virtual Healthcare Conference
finance.yahoo.com - April 29 at 7:25 PM
Earnings Preview: 10x Genomics (TXG) Q1 Earnings Expected to DeclineEarnings Preview: 10x Genomics (TXG) Q1 Earnings Expected to Decline
finance.yahoo.com - April 28 at 1:36 PM
PTAB Slashes 2 Bio-Rad DNA Patents In 10X Genomics FightPTAB Slashes 2 Bio-Rad DNA Patents In 10X Genomics Fight
law360.com - April 27 at 6:03 PM
10x Genomics (NASDAQ:TXG) Hits New 1-Year High at $203.2710x Genomics (NASDAQ:TXG) Hits New 1-Year High at $203.27
americanbankingnews.com - April 26 at 4:28 PM
10x Genomics, Inc. (NASDAQ:TXG) Is Expected To Breakeven In The Near Future10x Genomics, Inc. (NASDAQ:TXG) Is Expected To Breakeven In The Near Future
finance.yahoo.com - April 23 at 2:25 PM
DateCompanyBrokerageAction
2/12/2021Bio-Rad LaboratoriesCitigroupBoost Price Target
2/5/2021Bio-Rad LaboratoriesJefferies Financial GroupBoost Price Target
10/30/2020Bio-Rad LaboratoriesSmith Barney CitigroupBoost Price Target
10/30/2020Bio-Rad LaboratoriesWells Fargo & CompanyBoost Price Target
3/26/2020Bio-Rad LaboratoriesBarclaysLower Price Target
8/20/2019Bio-Rad LaboratoriesThe Goldman Sachs GroupUpgrade
5/9/2019Bio-Rad LaboratoriesDeutsche Bank AktiengesellschaftBoost Price Target
5/5/2021AvantorStifel NicolausUpgrade
5/5/2021AvantorRaymond JamesBoost Price Target
5/5/2021AvantorMorgan StanleyBoost Price Target
5/5/2021AvantorCredit Suisse GroupBoost Price Target
4/29/2021AvantorJPMorgan Chase & Co.Boost Price Target
4/29/2021AvantorRobert W. BairdBoost Price Target
4/29/2021AvantorPiper SandlerBoost Price Target
1/19/2021AvantorKeyCorpBoost Price Target
12/16/2020AvantorCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
5/12/2021WatersSVB LeerinkBoost Price Target
12/17/2020WatersCleveland ResearchUpgrade
7/28/2020WatersNeedham & Company LLCInitiated Coverage
4/29/2020WatersBank of AmericaLower Price Target
3/22/202110x GenomicsWilliam BlairInitiated Coverage
2/25/202110x GenomicsCowenBoost Price Target
(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.